These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 8072057)
1. Hypothesis that mesolimbic dopamine (DA) plays a key role in mediating the reinforcing effects of drugs of abuse as well as the rewarding effects of ingestive behaviors. Rothman RB; Gendron T; Hitzig P J Subst Abuse Treat; 1994; 11(3):273-5. PubMed ID: 8072057 [No Abstract] [Full Text] [Related]
3. Phentermine and fenfluramine. Preclinical studies in animal models of cocaine addiction. Rothman RB; Elmer GI; Shippenberg TS; Rea W; Baumann MH Ann N Y Acad Sci; 1998 May; 844():59-74. PubMed ID: 9668665 [TBL] [Abstract][Full Text] [Related]
4. Combination of the dopaminergic agent, phentermine, and the serotonergic agent, fenfluramine, in the treatment of cocaine dependence. Kampman KM; Volpicelli J J Subst Abuse Treat; 1997; 14(4):401-4. PubMed ID: 9368218 [No Abstract] [Full Text] [Related]
5. Phentermine pretreatment antagonizes the cocaine-induced rise in mesolimbic dopamine. Rothman RB; Ayestas M; Baumann MH Neuroreport; 1996 Dec; 8(1):7-9. PubMed ID: 9051742 [TBL] [Abstract][Full Text] [Related]
6. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909. Rothman RB; Glowa JR Mol Neurobiol; 1995; 11(1-3):1-19. PubMed ID: 8561954 [TBL] [Abstract][Full Text] [Related]
7. Supraadditive effect of d-fenfluramine plus phentermine on extracellular acetylcholine in the nucleus accumbens: possible mechanism for inhibition of excessive feeding and drug abuse. Rada PV; Hoebel BG Pharmacol Biochem Behav; 2000 Mar; 65(3):369-73. PubMed ID: 10683475 [TBL] [Abstract][Full Text] [Related]
8. The dopamine hypothesis of the reinforcing properties of cocaine. Kuhar MJ; Ritz MC; Boja JW Trends Neurosci; 1991 Jul; 14(7):299-302. PubMed ID: 1719677 [TBL] [Abstract][Full Text] [Related]
9. The combination of phentermine and fenfluramine reduced cocaine withdrawal symptoms in an open trial. Kampman KM; Rukstalis M; Pettinati H; Muller E; Acosta T; Gariti P; Ehrman R; O'Brien CP J Subst Abuse Treat; 2000 Jul; 19(1):77-9. PubMed ID: 10867304 [No Abstract] [Full Text] [Related]
10. Neural mechanisms of the reinforcing action of cocaine. Wise RA NIDA Res Monogr; 1984; 50():15-33. PubMed ID: 6440023 [TBL] [Abstract][Full Text] [Related]
11. [Psychopharmacological models of drug dependence. Key role of the dopaminergic mesolimbic system]. Wallnöfer A Schweiz Rundsch Med Prax; 1993 Sep; 82(37):999-1003. PubMed ID: 8210861 [TBL] [Abstract][Full Text] [Related]
12. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Pierce RC; Kumaresan V Neurosci Biobehav Rev; 2006; 30(2):215-38. PubMed ID: 16099045 [TBL] [Abstract][Full Text] [Related]
13. Role of serotonin in cocaine effects in mice with reduced dopamine transporter function. Mateo Y; Budygin EA; John CE; Jones SR Proc Natl Acad Sci U S A; 2004 Jan; 101(1):372-7. PubMed ID: 14691264 [TBL] [Abstract][Full Text] [Related]
14. Relationship between anorectic and reinforcing properties of appetite suppressant drugs: implications for assessment of abuse liability. Griffiths RR; Brady JV; Snell JD Biol Psychiatry; 1978 Apr; 13(2):283-90. PubMed ID: 96878 [TBL] [Abstract][Full Text] [Related]
15. Endogenous opioids and addiction to alcohol and other drugs of abuse. Gianoulakis C Curr Top Med Chem; 2004; 4(1):39-50. PubMed ID: 14754375 [TBL] [Abstract][Full Text] [Related]
16. Role for the mesocortical dopamine system in the motivating effects of cocaine. Koob GF; Caine B; Markou A; Pulvirenti L; Weiss F NIDA Res Monogr; 1994; 145():1-18. PubMed ID: 8742805 [TBL] [Abstract][Full Text] [Related]
18. Psychostimulant drugs and a dopamine hypothesis regarding addiction: update on recent research. Ritz MC; Kuhar MJ Biochem Soc Symp; 1993; 59():51-64. PubMed ID: 7910741 [TBL] [Abstract][Full Text] [Related]
19. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Weintraub M; Sundaresan PR; Madan M; Schuster B; Balder A; Lasagna L; Cox C Clin Pharmacol Ther; 1992 May; 51(5):586-94. PubMed ID: 1587072 [TBL] [Abstract][Full Text] [Related]
20. Fenfluramine: amphetamine congener that fails to maintain drug-taking behavior in the rhesus monkey. Woods JH; Tessel RE Science; 1974 Sep; 185(4156):1067-9. PubMed ID: 4212011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]